Treatment of Liver Cell Adenoma ≥ 5 cm in Female Patients
In women with a hepatic adenoma confirmed at 5 cm or larger, a defined first-line management pathway applies — centred on a structured observation period with clear clinical targets and specific modifiable factors to address.
Clinical scenario
This protocol is indicated for female patients with a hepatocellular adenoma measuring 5 cm or larger. Both the patient's sex and the lesion size together define this specific management pathway.
First-line approach
Management begins with addressing exogenous hormone exposure and, where applicable, weight. The complete protocol — including the full stepwise algorithm, observation schedule, and escalation criteria — is available in the structured regimen below.
Clinical goal
The primary target during the observation period is regression of the hepatic adenoma to below 5 cm. The protocol specifies the imaging follow-up and the next steps depending on whether this target is achieved.
References
DOI: 10.14309/ajg.0000000000002857
- For females with HCAs that are 5 cm or larger, a period of 6 months of observation is reasonable with cessation of exogenous hormone use (OCPs, hormonal intrauterine devices, and anabolic steroids) and, if applicable, a recommendation for weight loss.
- Women with hepatic adenomas ≥5 cm should modify risk factors, undergo observation for 6–12 months, and undergo resection if the lesion does not regress to <5 cm.
- If during the observation period, the adenoma has regressed to <5 cm, continued observation with contrast-enhanced MRI is recommended.